Domestic price of Ado-trastuzumab emtansine

Ado-trastuzumab emtansine is a drug-antibody conjugate that has shown promising results in patients who have failed previous treatment with trastuzumab. TrastuzumabConsists of the monoclonal antibody trastuzumab linked to a potent microtubule inhibitor (emtansine), allowing targeted delivery of chemotherapy to cells that overexpress HER2. Trastuzumab is approved for patients with metastatic breast cancer who have failed prior trastuzumab and taxane therapy.

Human epidermal growth factor receptor-2 (HER2)-positive breast cancer is an aggressive form of breast cancer that is associated with poor prognosis and shortened survival. Although trastuzumab was well tolerated in clinical trials, thrombocytopenia has been reported and platelet values u200bu200bshould be monitored closely. Increased liver enzymes and bilirubin as well as cardiotoxicity have also been documented, and dose reduction or discontinuation has been recommended due to these toxicities.

EnmetratrastuzumabThe monoclonal antigenic drug has been launched in China and has entered the scope of medical insurance. Reimbursement is limited to eligible patients. This drug is a strictly controlled drug. The price of 100 mg per box may be around 20,000 yuan, and the price of 160 mg per box may be around 30,000 yuan. The expensive price may increase the financial burden of some families. Listed overseas Enmei Trastuzumab The single-unit generic drug has Turkish and European versions, with specifications The price of each box of 100 mg may be around 3,000-8,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of the originator drugs sold domestically and abroad are basically the same, and there are currently no generic versions of Enmei Trastuzumab produced and launched.